{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:04:04Z","timestamp":1790744644716,"version":"4.1.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the hypothesis that 3 novel compounds, OXT-328, Q-922, and CL-717 show efficacy in the treatment of oxygen-induced retinopathy (OIR) and whether or not their route of administration is intravitreal, topical, or systemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The OIR mouse model, characterized by an avascular area (AVA) and a neovascular area (NVA) of the retina, was used to study retinopathy of prematurity and other retinal diseases characterized by abnormal vessel growth. We measured the effect of our compounds on both the AVA and NVA in whole mounts of mouse retinal tissue. We also evaluated their ability to prevent new vessel formation in chicken chorioallantoic membranes (CAMs). Finally, we measured the\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      uptake and biodistribution of topically applied CL-717 in human eye explants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In mice with OIR, compared to controls, a single intravitreal administration of Q-922 or OXT-328 significantly reduced both AVA and NVA. CL-717 administered as eye drops over 5 days also reduced AVA and NVA, whereas OXT-328 eye drops had no effect. Q-922 given intraperitoneal (150\u2009mg\/kg\/day\u2009\u00d7\u20095 days) reduced AVA and NVA. Remarkably, explanted human eyes bathed in CL-717 show rapid uptake and biodistribution in ocular tissues. In the chicken CAM model, all 3 compounds reduced the formation of new blood vessels by about one-third. No side effect in mice was observed, except for mild ocular surface irritation with Q-922.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Systemic administration of Q-922 or topical administration of CL-717 holds particular promise for a simplified treatment of proliferative retinopathies without the necessity of intravitreal injections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2022.0113","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T16:14:07Z","timestamp":1683908047000},"page":"279-289","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["The Antiangiogenic Effect and Ocular Pharmacology of Novel Modified Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Oxygen-Induced Retinopathy"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5932-6510","authenticated-orcid":false,"given":"Wei","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Population and Preventive Medicine, Stony Brook University, Stony Brook, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Huang","sequence":"additional","affiliation":[{"name":"Medicon Pharmaceuticals, Inc., Setauket, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Wen","sequence":"additional","affiliation":[{"name":"Medicon Pharmaceuticals, Inc., Setauket, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Honkanen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Population and Preventive Medicine, Stony Brook University, Stony Brook, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1758-6939","authenticated-orcid":false,"given":"Basil","family":"Rigas","sequence":"additional","affiliation":[{"name":"Department of Family, Population and Preventive Medicine, Stony Brook University, Stony Brook, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"e_1_3_6_2_2","first-page":"20","article-title":"Curr","volume":"18","author":"Higgins RD","year":"1999","unstructured":"Higgins RD, , Yu K, , Sanders RJ, , Nandgaonkar BN, , Rotschild T, , Rifkin DB. Diltiazem reduces retinal neovascularization in a mouse model of oxygen induced retinopathy. Curr. Eye Res. 18:20\u201327, 1999.","journal-title":"Eye Res"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2007.05.007"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/70963"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2009.306"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.5409\/wjcp.v5.i1.35"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29683"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201700336R"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20001215)88:6<873::AID-IJC6>3.0.CO;2-B"},{"key":"e_1_3_6_10_2","first-page":"869","article-title":"line","volume":"21","author":"Segawa E","year":"2009","unstructured":"Segawa E, , Hashitani S, , Toyohara Y, , Kishimoto H, , Noguchi K, , Takaoka K, , Urade M, . Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell. line. Oncol Rep. 21:869\u2013874, 2009.","journal-title":"Oncol Rep"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-5987com"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12250"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.044"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1577"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2190"},{"key":"e_1_3_6_16_2","unstructured":"Cheng K-W Ren J Kathawala R Wong C Mattheolabakis G Wen Z Noutsos C Huang L Rigas B. Phospho-sulindac (OXT-328) is efficacious in the treatment of lung cancer: A redox dominated effect Molecular Cancer Therapeutics. 2018; Submitted."},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.188508"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2010.084657"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2018.05.005"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77254-0"},{"key":"e_1_3_6_21_2","first-page":"22","article-title":"Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye","author":"Santonocito M","year":"2021","unstructured":"Santonocito M, , Zappulla C, , Viola S, , La Rosa LR, , Solfato E, , Abbate I, , Tarallo V, , Apicella I, , Platania CBM, , Maugeri G, , D'Agata V, , Bucolo C, , De Falco S, , Mazzone MG, , Giuliano F. Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye. Int J Mol Sci. 22, 2021.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_6_22_2","first-page":"11","article-title":"Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration","author":"Garcia-Quintanilla L","year":"2019","unstructured":"Garcia-Quintanilla L, , Luaces-Rodriguez A, , Gil-Martinez M, , Mondelo-Garcia C, , Maronas O, , Mangas Sanjuan V, , Gonzalez-Barcia M, , Zarra-Ferro I, , Aguiar P, , Otero-Espinar FJ, , Fernandez-Ferreiro A. Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. Pharmaceutics. 11, 2019.","journal-title":"Pharmaceutics"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6491"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01705.x"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.12.057"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-014-9440-7"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.220806"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.01162.x"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2349"},{"key":"e_1_3_6_30_2","first-page":"1471","article-title":"Pharm","volume":"30","author":"Mattheolabakis G","year":"2013","unstructured":"Mattheolabakis G, , Mackenzie GG, , Huang L, , Ouyang N, , Cheng KW, , Rigas B. Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats. Pharm. Res. 30:1471\u20131482, 2013.","journal-title":"Res"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/106594"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S94447"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-017-0913-0"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S94449"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2018.04.002"},{"key":"e_1_3_6_36_2","article-title":"Comparative Localization of Carboxylesterase 1 and 2, Butyrylcholinesterase and Acetylcholinesterase in Human, Primate and Rabbit Ocular Tissues","volume":"53","author":"Raymond I","year":"2012","unstructured":"Raymond I, , Nie R, , Ren M, , Ramos M. Comparative Localization of Carboxylesterase 1 and 2, Butyrylcholinesterase and Acetylcholinesterase in Human, Primate and Rabbit Ocular Tissues. Investigative Ophthalmology and Visual Science, 53, 2012.","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"e_1_3_6_37_2","first-page":"1305","article-title":"Mol","volume":"18","author":"Hammid A","year":"2021","unstructured":"Hammid A, , Fallon JK, , Lassila T, , Salluce G, , Smith PC, , Tolonen A, , Sauer A, , Urtti A, , Honkakoski P, . Carboxylesterase Activities and Protein Expression in Rabbit and Pig Ocular Tissues. Mol. Pharm. 18:1305\u20131316, 2021.","journal-title":"Pharm"},{"key":"e_1_3_6_38_2","first-page":"3913","article-title":"Comparison of pH Values of Selected Ocular Lubricants","volume":"45","author":"Perrigin JA","year":"2004","unstructured":"Perrigin JA, , Morgan A, , Quintero S, , Perrigin D, , Brown S, , Bergmanson J. Comparison of pH Values of Selected Ocular Lubricants. Invest. Ophthalmol. Vis. Sci. 45:3913\u20133913, 2004.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.02.044"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H"},{"key":"e_1_3_6_41_2","first-page":"133","article-title":"Diseases","volume":"2","author":"Heisel C","year":"2021","unstructured":"Heisel C, , Yousif J, , Mijiti M, , Charizanis K, , Brigell M, , Corson TW, , Kelley MR, . APE1\/Ref-1 as a Novel Target for Retinal. Diseases. J Cell Signal. 2:133\u2013138, 2021.","journal-title":"J Cell Signal"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2022.0113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2022.0113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2022.0113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:45:22Z","timestamp":1777646722000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2022.0113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5,1]]}},"alternative-id":["10.1089\/jop.2022.0113"],"URL":"https:\/\/doi.org\/10.1089\/jop.2022.0113","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}